DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for muscular atrophy — screening already-approved drugs against its 24-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMuscular atrophy maps to a 24-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for muscular atrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 1 receptor associated kinase 3 (IRAK3) — IRAK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet agsdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIW · 2.18 Å · ligand PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER (AGS). Experimental structure, not a prediction.
What the evidence adds up to
In 2019, a mini-review noted that the first SMN genetic therapy for spinal muscular atrophy had recently been approved and that other SMN-dependent treatments were close behind, but that not all patients would benefit fully due to limited accessibility, high costs, and differential effects depending on timing of administration and disease severity. The review proposed repurposing commercially available drugs for neurodegenerative, neuromuscular and muscle disorders as a faster and cheaper route to new treatments. A 2024 review of repurposed drugs for SMA listed branaplam, riluzole, olesoxime, harmine, and prednisolone as having shown some improvement, but stated that the current repurposing strategy lacks systematicity and often depends on serendipitous discoveries rather than organised approaches.
A 2024 systematic review of SMA diagnosis, treatment and emerging research identified 40 publications covering the three approved drugs — risdiplam, onasemnogene abeparvovec, and nusinersen — and studies comparing them, as well as drugs including hydroxyurea, phenylbutyrate, and gabapentin. All three approved drugs improved motor milestones compared to the natural disease course. Gene replacement therapy showed tremendous results but the review stated further investigation is needed. Among the other drugs, hydroxyurea and valproic acid showed slight improvement, while gabapentin and phenylbutyrate had no effect. The same review noted that SMA is incurable, though various drugs have been developed to ameliorate the condition.
A 2018 position statement on sharing clinical research data in SMA acknowledged unprecedented advancements in understanding genetic determinants, natural history, outcome measures, and the first marketed therapies, but stated plainly that many patients do not yet benefit from effective treatments or show limited clinical response or impact on their quality of life. A 2012 account of the discovery of an antisense-based therapy for SMA described the eight-year journey from basic biology to a promising drug candidate, but provided no numerical efficacy data.
What remains missing is a methodical, target-driven approach to drug repurposing for SMA, as current efforts are largely unsystematic. The high cost and limited accessibility of existing genetic therapies mean that many patients still lack effective treatment, and no repurposed drug has yet demonstrated consistent, clinically meaningful benefit in a properly powered trial. Stratification by disease severity and timing of administration will be needed to determine which patients, if any, might gain from these older drugs.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Cell Biology · 2012 · 172 citations · open access
Antisense-based therapy for the treatment of spinal muscular atrophy
AbstractOne of the greatest thrills a biomedical researcher may experience is seeing the product of many years of dedicated effort finally make its way to the patient. As a team, we have worked for the past eight years to discover a drug that could treat a devastating childhood neuromuscular disease, spinal muscular atrophy (SMA). Here, we describe the journey that has led to a promising drug based on the biology underlying the disease.
Journal of Neuromuscular Diseases · 2018 · 10 citations · open access
Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients
AbstractRecent years have seen increasing clinical research activities in spinal muscular atrophy (SMA), involving patients, their families, clinicians, researchers, regulators and industry This has led to unprecedented advancements in understanding of genetic determinants of severity and prognosis, the natural history, outcome measures, and most importantly first marketed therapies However, many patients with SMA do not benefit yet from effective treatments or show limited clinical response or impact on their quality of life.
Future Neurology · 2019 · 9 citations · open access
Teaching An Old Drug New Tricks: Repositioning Strategies for Spinal Muscular atrophy
AbstractSpinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hallmarks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far behind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs and differential effects depending on timing of administration and disease severity. The repurposing of commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.
Cellular and Molecular Neurobiology · 2024 · 5 citations · open access
Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs
AbstractSpinal muscular atrophy (SMA) is an autosomal recessive genetic neuromuscular disorder that is characterized by gradual muscle weakness and atrophy due to the degeneration of alpha motor neurons that are present on the anterior horn of the spinal cord. Despite the comprehensive investigations conducted by global scientists, effective treatments or interventions remain elusive. The time- and resource-intensive nature of the initial stages of drug research underscores the need for alternate strategies like drug repurposing. This review explores the repurposed drugs that have shown some improvement in treating SMA, including branaplam, riluzole, olesoxime, harmine, and prednisolone. The current strategy for medication repurposing, however, lacks systematicity and frequently depends more on serendipitous discoveries than on organized approaches. To speed up the development of successful therapeutic interventions, it is apparent that a methodical approach targeting the molecular origins of SMA is strictly required.
International Journal of Pharmaceutical Sciences and Drug Research · 2024 · 0 citations · open access
Spinal Muscular Atrophy: A Systematic Review of Diagnosis, Treatment and Emerging Research
AbstractThis systematic review aims at understanding the causes, consequences and therapy of spinal muscular atrophy, which is an inheritable illness which can be fatal at times. Although spinal muscular atrophy is incurable, various drugs have been developed to ameliorate the disease condition and this article aims at understanding the effect of all the available synthetic drugs on Spinal muscular atrophy (SMA). A search plan was curated using various databases like, PubMed, Google Scholar and Science Direct. Authors selected publications of Risdiplam, Onasemnogene abeparvovec and Nusinersen, and even studies comparing the drugs with one another, including studies related to drugs like hydroxyurea, phenylbutyrate and gabapentin. 40 publications were identified and finalized based on preferences. All the 3 approved drugs improved motor milestones in SMA patients as compared to natural cohort of the disease. Although Gene replacement therapy observed tremendous results, further investigations is needed to be done. Other drugs like hydroxyurea (HU), Gabapentin, Valproic acid and phenylbutyrate showed significant, little and no effect respectively. All 3 drugs showed significant outcomes and were safe and effective in the longer duration of use. Hydroxyurea and Valproic acid showed slight improvement whereas Gabapentin and Phenylbutyrate had no effect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
